close
MENU
How to guide
How to guide
Home
NBR Marketplace
The NBR List
NBR Video

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Marketing & Media Tourism Energy Luxury Property Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

The NBR Podcast Morning Brew The Grind Entrepreneurs Your Business Beehive Banter Toil & Trouble Market Outlook Dollars & Sense Local Edge Private Bin Audio Articles Podcasts NZ Aviation News Back Issues NBR Radar (Archive) Opinion (Archive) NBR Rich List (Archive)
General Business
2 mins to read

Movac funds shrink stake in ASX-listed Aroa Biosurgery

Movac was quick to divest some Aroa shares after being freed from post-IPO escrow.

Julie Iles Fri, 05 Feb 2021

New Zealand-based investment firm Movac was quick to sell a portion of its shares in Aroa Biosurgery as soon as it could after the biotech company's ASX-listing in June. 

The Movac Fund 3 and Movac Sidecar 3 Fund sold millions of shares in Aroa - shrinking the firm's stake in the soft tissue

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Already have an account? Login
Julie Iles Fri, 05 Feb 2021
Contact the Writer: julie@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
Movac Aroa Biosurgery

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
General Business

Aroa debuts on ASX ahead of schedule
General Business
2

NZ biotech IPO valued at $240m

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News
General Business

Aroa debuts on ASX ahead of schedule
General Business
2

NZ biotech IPO valued at $240m
Movac funds shrink stake in ASX-listed Aroa Biosurgery
General Business,
86266
true
Subscribe Login